EPHA2 and cancer: Compared to the EphA2 expression in malignant melanoma, normal tissues have low EphA2 expression, and therefore using YSA peptide-anchored nanocarriers for drug delivery may reduce off target side effects by reducing exposure of cytotoxic drugs to normal cells [21].